Numerous clinical studies have established that angiotensin II receptor blockers are effective as antihypertensive therapy and are well tolerated. Studies demonstrate that adding an angiotensin II ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Abstract We investigated the effects of angiotensin II (Ang II) type 1 receptor blockade with losartan on the renin-angiotensin-aldosterone system in hypertensive patients (supine diastolic blood ...

Therefore, we examined the effect of IL-6 on AT 1 receptor expression in vitro and in vivo and the potential relevance for the onset of endothelial dysfunction. Recombinant mouse IL-6 was obtained ...

Seasonal influenza, respiratory syncytial virus (RSV), and COVID-19 are actively circulating throughout the United States.

1), although many of the leading compounds are available as generics. In terms of branded sales, the angiotensin II receptor blocker class dominates with five of the top ten antihypertensives ...

Dimerix has achieved a key milestone in its ACTION3 phase III trial of lead asset DMX-200 into focal segmental ...

The angiotensin receptor–neprilysin inhibitor, sacubitril/valsartan, simultaneously augments the natriuretic peptide system (NPS) by inhibiting the enzyme neprilysin (NEP) and inhibits the ...

The following is a summary of “Monocytic reactive oxygen species-induced T cell apoptosis impairs cellular immune response to ...

Hypertension, also known as high blood pressure, is the most common cardiovascular risk factor. It describes a condition where the force of blood pushing against the walls of blood vessels called ...

A recent study from Columbia University has raised important questions about the medications used to treat high blood ...

Design Cultured human colonic myofibroblast proliferation and collagen secretion were assessed following treatment with angiotensin (Ang) II and Ang (1–7), their receptor antagonists candesartan and ...